DeepRad.AI: Revolutionising medical imaging with AI innovation

Founded by Professor Cheng-Yu Chen of Taipei Medical University (TMU), DeepRad.AI is transforming the future of radiology through the integration of advanced artificial intelligence technologies and medical imaging. With a mission to bridge the gap between clinical practice and AI innovation, the company leverages the expertise of experienced radiologists and AI engineers to enhance diagnostic precision, reduce interpretation time, and improve patient outcomes. DeepLung-CAC: Dual Screening with a Single LDCT Scan DeepRad.AI's flagship product,DeepLung-CAC, is an AI-powered pulmonary-coronary screening platform that utilizes a single low-dose computed tomography (LDCT) scan to simultaneously assess the risk of pulmonary nodules and coronary artery calcification (CAC). This dual-purpose screening not only improves efficiency but also reduces radiation exposure and costs associated with multiple tests. The platform is certified by the Taiwan Food and Drug Administration (TFDA) and recognized as the first domestically developed AI pulmonary-coronary screening system. One of its standout features is the LungRads module, which incorporates deep learning models for nodule detection, segmentation, and classification, trained on over 6,000 CT cases. Powered by state-of-the-art 3D deep learning, DeepLung-CAC can complete detailed analyses in under one minute. Professor Chen emphasizes the significance of early detection in improving lung cancer survival rates. While traditional methods often require 25 to 30 minutes of physician review time, DeepLung-CAC reduces interpretation time to just 5 minutes—enabling radiologists to efficiently analyze images and provide quicker diagnoses. The platform also supports multi-disease risk assessment from a single scan, enhancing its clinical utility. DeepBrain-Cognito: Personalized Dementia Risk Assessment Beyond thoracic imaging, DeepRad.AI has also developed DeepBrain-Cognito, a computational model designed for the early detection of cognitive decline. This platform provides personalized risk assessments for populations with suboptimal health, such as the elderly or those with chronic conditions. By integrating AI with large-scale brain imaging data, DeepBrain-Cognito enables timely intervention for neurodegenerative diseases such as dementia and Alzheimer’s disease. Recognition and Future Directions In 2024, DeepRad.AI’s innovations were widely recognized. The company received several prestigious awards, including:

• Future Tech Award
• NBRP Pitch Day Outstanding Team Award
• GenAI Stars Quality Innovation Award
• National Pharmaceutical Technology & Research Development Award

These accolades reflect the platform's strong potential for real-world clinical applications and its role in driving forward Taiwan’s biomedical AI industry. By combining AI with medical expertise, DeepRad.AI continues to push the boundaries of radiology, aiming to create faster, more accurate, and accessible diagnostic tools for global healthcare systems.